Pregled bibliografske jedinice broj: 817976
Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP
Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP // ESMO Open, 2016 (2016), 1-4 doi:10.1136/esmoopen-2016-000049 (recenziran, članak, stručni)
CROSBI ID: 817976 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP
(Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP))
Autori
Fröbe, Ana ; Murgić, Jure ; Stefan, Rauh
Izvornik
ESMO Open (2059-7029) 2016
(2016);
1-4
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni
Ključne riječi
abiraterone acetate; mCRPC; reallife clinical setting
Sažetak
U radu su opisana klinička iskustva s terapijom abirateron acetatom te je potvrđena sigurnost primjene i željeni terapijski učinak u neselektiranoj populaciji bolesnika s kastracijski rezistentnim karcinomom prostae.
Izvorni jezik
Engleski
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- SCI-EXP, SSCI i/ili A&HCI
